Sabra Healthcare REIT’s (SBRA) Buy (B) Rating Reiterated at Weiss Ratings

Sabra Healthcare REIT (NASDAQ:SBRA)‘s stock had its “buy (b)” rating reiterated by investment analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Several other research analysts also recently issued reports on SBRA. BMO Capital Markets upped their price objective on Sabra Healthcare REIT from $19.00 to $22.00 and gave the stock a “market perform” rating in a report on Monday, August 25th. JMP Securities upped their price objective on Sabra Healthcare REIT from $20.00 to $22.00 and gave the stock a “market outperform” rating in a report on Wednesday, August 6th. Cantor Fitzgerald assumed coverage on Sabra Healthcare REIT in a report on Wednesday, October 1st. They set a “neutral” rating and a $20.00 price objective on the stock. Wells Fargo & Company upped their price objective on Sabra Healthcare REIT from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Wednesday, August 27th. Finally, Truist Financial upped their price objective on Sabra Healthcare REIT from $18.00 to $20.00 and gave the stock a “hold” rating in a report on Tuesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $20.71.

Sabra Healthcare REIT Stock Down 0.2%

Shares of SBRA opened at $17.98 on Wednesday. The company has a market capitalization of $4.31 billion, a P/E ratio of 23.66, a PEG ratio of 1.21 and a beta of 0.85. The company has a debt-to-equity ratio of 0.91, a current ratio of 4.80 and a quick ratio of 4.80. Sabra Healthcare REIT has a one year low of $15.60 and a one year high of $20.03. The business’s 50 day simple moving average is $18.77 and its 200-day simple moving average is $18.16.

Sabra Healthcare REIT (NASDAQ:SBRA) last announced its earnings results on Monday, August 4th. The real estate investment trust reported $0.38 EPS for the quarter, topping the consensus estimate of $0.36 by $0.02. Sabra Healthcare REIT had a return on equity of 6.69% and a net margin of 24.87%.The business had revenue of $189.15 million for the quarter, compared to the consensus estimate of $185.64 million. During the same period in the previous year, the business earned $0.36 EPS. Sabra Healthcare REIT’s revenue was up 7.4% compared to the same quarter last year. Sabra Healthcare REIT has set its FY 2025 guidance at 1.450-1.470 EPS. As a group, sell-side analysts predict that Sabra Healthcare REIT will post 1.45 EPS for the current fiscal year.

Institutional Trading of Sabra Healthcare REIT

Several institutional investors and hedge funds have recently made changes to their positions in SBRA. Nuveen LLC bought a new stake in shares of Sabra Healthcare REIT during the 1st quarter valued at $61,791,000. Engineers Gate Manager LP increased its position in shares of Sabra Healthcare REIT by 3,190.3% in the 2nd quarter. Engineers Gate Manager LP now owns 3,179,303 shares of the real estate investment trust’s stock valued at $58,626,000 after buying an additional 3,082,677 shares in the last quarter. Norges Bank bought a new stake in shares of Sabra Healthcare REIT in the 2nd quarter valued at $54,385,000. Balyasny Asset Management L.P. bought a new stake in shares of Sabra Healthcare REIT in the 2nd quarter valued at $49,955,000. Finally, Bank of Montreal Can increased its position in shares of Sabra Healthcare REIT by 244.1% in the 2nd quarter. Bank of Montreal Can now owns 2,575,969 shares of the real estate investment trust’s stock valued at $47,501,000 after buying an additional 1,827,361 shares in the last quarter. Institutional investors own 99.40% of the company’s stock.

About Sabra Healthcare REIT

Sabra Health Care REIT, Inc engages in the business of acquiring, financing, and owning real estate property. The company was founded on May 10, 2010 and is headquartered in Tustin, CA.